Sign in to view content

PER-001, a Long-acting Endothelin Antagonist Intravitreal Implant, Improved Structure and Visual Function in Patients With Diabetic Retinopathy

Justis P. Ehlers, MD, FASRS

Video
Published 2025

Related

Cost-Effectiveness of Aflibercept Monotherapy vs Bevacizumab-First Followed by Switching to Aflibercept if Needed for Diabetic Macular Edema
Mathew W. MacCumber, MD, PhD
Annual Meeting Talks
2023
Imaging, Digital, Angiography Symposium 1
Annual Meeting Talks
2020
PRISM Phase 2b Clinical Trial Evaluating Intravitreal 4D-150 in Adults With Neovascular Age-Related Macular Degeneration: 52-Week Results
John A. Wells, MD, FACS
Updates from the Field
2025

Category: Diabetic Retinopathy

See more